Cytokine therapy for metastatic renal cell carcinoma.

摘要: Cytokine therapy for patients with metastatic renal cancer is based on observations suggesting this neoplasm may be responsive to immunotherapy. Two cytokines, interferon-alpha (IFN-alpha) and interleukin 2 (IL-2) produce tumor regressions in 10% 15% of disease. Randomized trials demonstrate a modest survival advantage treated IFN-alpha. Combinations IL-2 IFN-alpha appear associated improved response rates, but no demonstrable effect survival. Additions other cytokines (eg, GM-CSF) or chemotherapy combination has been investigated, results do not suggest they enhance the outcome. Patient selection remains an important issue patient population. Individuals who are asymptomatic have limited pulmonary soft-tissue disease most likely benefit. The roles immune dysregulation addition novel cytostatic agents these regimens under investigation.